Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this research is to determine the benefit of two oral chemotherapy drugs,
Vemurafenib and Sorafenib, in individuals with KRAS G12D mutated pancreatic cancer who have
progressed on standard chemotherapy.